信邦製藥(002390.SZ):法院受理公司控股股東之一致行動人譽衡集團破產重整
格隆匯 7 月 6日丨信邦製藥(002390.SZ)公佈,2020年7月6日,公司收到控股股東西藏譽曦創業投資有限公司(“西藏譽曦”)之一致行動人哈爾濱譽衡集團有限公司(“譽衡集團”)的通知,譽衡集團收到《黑龍江省哈爾濱市中級人民法院民事裁定書》(【2020】黑01破申1號),法院裁定受理了譽衡集團債權人對譽衡集團的破產重整申請。
譽衡集團債權人以譽衡集團無法清償到期債務且資產不足以清償全部債務為由,向黑龍江省哈爾濱市中級人民法院申請對譽衡集團進行破產重整。黑龍江省哈爾濱市中級人民法院受理了此案,並裁定如下:受理譽衡集團債權人對譽衡集團的破產重整申請。
截至公告日,西藏譽曦持有公司股份約3.59億股,佔公司總股本比例的21.52%,其所持公司股份全部被質押並被司法凍結。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.